EUVIMEDEUVIMED entdecken
Crossref

Immune checkpoint inhibitor-induced vitiligo in cancer patients: characterization and management

Jonathan Lo, Hannah L Hanania, Monika F Keiser, Anisha B Patel

Archives of Dermatological Research · 2023

DOI: 10.1007/s00403-023-02577-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archives of Dermatological Research, 2023. Verfasst von Jonathan Lo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Baylor College of Medicine, Houston, TX, USA. Hauptthemen laut MEDLINE: Vitiligo, Skin Neoplasms, Ultraviolet Therapy. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study highlights the range of non-melanoma cancers where ICI-induced vitiligo can be present and challenges the exclusivity of this phenomenon to melanoma. We believe our manuscript will encourage awareness in our colleagues and stimulate interest in further studies to elucidate the mechanisms of ICI-induced vitiligo in both melanoma and non-melanoma cancers, and to understand whether this phenomenon holds the same positive prognostic value in both cancer groups. This is a retrospective cohort study from a single-institution's electronic medical record for cancer patients treated with ICIs who subsequently developed vitiligo. We identified 151 patients with ICI-induced vitiligo, 19 (12.6%) non-melanoma and 132 (77.4%) melanoma patients. Time to onset of vitiligo was nearly doubled in the non-melanoma cohort, however, this is confounded by possible delayed diagnosis or under reporting of this asymptomatic condition in patients who do not regularly receive skin exams. The majority of patients had a stable course of vitiligo with 91.4% receiving no treatment in this largely Caucasian cohort. Two patients with non-melanoma cancers and Fitzpatrick type IV or above skin received treatment with narrowband ultraviolet B light therapy and topical steroids with near-complete response. This study highlights the occurrence of ICI-induced vitiligo in a variety of non-melanoma cancers, where skin of color patients will be more prevalent and the need for treatment will potentially be more urgent. Further study is needed to elucidate the mechanism of ICI-induced vitiligo and determine if non-melanoma cancers have the same association between vitiligo and increased tumor response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VitiligoSkin NeoplasmsUltraviolet TherapyHumansImmune Checkpoint InhibitorsRetrospective Studies

Stichwörter der Autor:innen

Cutaneous adverse eventsImmune checkpoint inhibitorNon-melanomaVitiligo

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Baylor College of Medicine, Houston, TX, USA.
  • University of Texas McGovern Medical School, Houston, TX, USA.
  • Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Apatel11@mdanderson.org.

Zitieren

APA

Lo, J., Hanania, H. L., Keiser, M. F., & Patel, A. B. (2023). Immune checkpoint inhibitor-induced vitiligo in cancer patients: characterization and management. Archives of Dermatological Research. https://doi.org/10.1007/s00403-023-02577-7

Vancouver

Lo J, Hanania HL, Keiser MF, Patel AB. Immune checkpoint inhibitor-induced vitiligo in cancer patients: characterization and management. Archives of Dermatological Research. 2023. doi:10.1007/s00403-023-02577-7

BibTeX
@article{Lo2023,
  author = {Lo, Jonathan and Hanania, Hannah L and Keiser, Monika F and Patel, Anisha B},
  title = {Immune checkpoint inhibitor-induced vitiligo in cancer patients: characterization and management},
  journal = {Archives of Dermatological Research},
  year = {2023},
  doi = {10.1007/s00403-023-02577-7}
}
Kostenlos starten →